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Porcine adenoviruscluding bovine adenovirus serotype 3 (BAd3) and porcine adenovirus serotype
3 (PAd3) can circumvent pre-existing immunity against human adenovirus serotype 5 (HAd5) and are
being developed as alternative vectors for gene delivery. To assess the usefulness of these vectors for in
vivo gene delivery, we compared biodistribution, persistence, state of vector genome, and transgene and
vector gene expression by replication-defective BAd3 and PAd3 vectors with those of HAd5 vector in a
FVB/n mouse model following intravenous inoculation. BAd3 vector efﬁciently transduced the heart,
kidney and lung in addition to the liver and spleen and persisted for a longer duration compared to PAd3
or HAd5 vectors. Biodistribution of PAd3 vector was comparable to that of HAd5 vector but showed more
rapid vector clearance. Only linear episomal forms of BAd3, PAd3, and HAd5 vector genomes were
detected. All three vectors efﬁciently expressed the green ﬂuorescent protein (GFP) transgene
proportionate to the vector genome copy number in various tissues. Furthermore, leaky expression of
vector genes, both the early (E4) and the late (hexon) was observed in all three vectors and gradually
declined with time. These results suggest that BAd3 and PAd3 vectors could serve as an alternative or
supplement to HAd5 for gene delivery applications.
© 2009 Elsevier Inc. All rights reserved.Introduction
Adenoviral (Ad) vectors have demonstrated great promise as
therapeutic and prophylactic gene delivery systems (McConnell and
Imperiale, 2004; Russell, 2000). Numerous advantages offered by Ad
vectors include the ease of large scale production, ease of genetic
manipulation, the lack of genomic integration, a relatively nonpatho-
genic nature, and their ability to transduce both dividing and non-
dividing cells. Vectors based on human adenovirus (HAd) serotype 5
(HAd5) and HAd serotype 2 (HAd2) are currently most widely
studied (Edelstein et al., 2004; Tatsis and Ertl, 2004). Attachment of
HAd5 and HAd2 to a susceptible cell is mediated by the high-afﬁnity
binding of the Ad ﬁber knob to a primary receptor, coxsackievirus and
Ad receptor (CAR) (Bergelson et al., 1997), followed by a secondary
interaction of the penton base with integrins resulting in virus
internalization into the cell (Wickham et al., 1993). This feature posestive Pathobiology, School of
, IN 47907, USA. Fax: +1 765
ll rights reserved.a challenge in targeting of Ad to speciﬁc tissues due to the wide
distribution of CAR in a variety of cell types. Preferential sequestration
of systemically administered Ad vectors to the liver (hepatotropism)
also leads to inefﬁcient transduction of target organs other than liver
and at high vector doses, poses serious adverse effects (Raper et al.,
2003). Furthermore, due to the endemic nature of HAd5 and HAd2,
pre-existing vector immunity may potentially inhibit the levels and
duration of transgene expression following inoculation with an Ad
vector. Vector-associated toxicity and induction of strong innate
immunity are some of the other potential concerns for these vectors.
In order to expand the repertoire of Ad vectors, vectors based on
less prevalent HAd serotypes such as HAd3, HAd11, and HAd35, or
nonhuman adenoviruses such as bovine adenovirus type 3 (BAd3),
porcine adenovirus type 3 (PAd3), ovine adenovirus, canine adeno-
virus, simian adenoviruses, and fowl adenovirus, are being investi-
gated as an alternative or supplement to HAd5 vectors (Bangari and
Mittal, 2006b; Farina et al., 2001; Hofmann et al., 1999; Kanerva et al.,
2002; Kremer et al., 2000; Michou et al., 1999; Reddy et al., 1999a,
1999b; Seshidhar Reddy et al., 2003; Stone et al., 2005). Vectors based
on nonhuman Ad or chimeric HAd vectors carrying the knob domain
or entire ﬁber from nonhuman Ad have been developed that
demonstrated novel and expanded tropism, in addition to evading
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2004; Singh et al., 2008).
We have demonstrated that nonhuman Ad vectors based on PAd3
and BAd3 efﬁciently transduce several types of human andmurine cells
in culture (Bangari et al., 2005b). These vectors appeared to utilize
distinct receptors for cell internalization (Bangari and Mittal, 2005;
Bangari et al., 2005a) and cell entry was independent of CAR. Most
importantly, we also showed that there were no pre-existing virus
neutralizing antibodies against PAd3 or BAd3 in humans, and HAd5-
neutralizing antibodies in human or raised in mice did not cross-
neutralize PAd3 or BAd3 (Bangari et al., 2005b; Moffatt et al., 2000).
In the present study, we assessed the usefulness of replication-
defective PAd3 and BAd3 vectors carrying the green ﬂuorescent
protein (GFP) gene as a reporter for in vivo gene delivery.
Biodistribution, persistence, the state of the vector genome, trans-
gene, and vector gene expression of these nonhuman Ad vectors were
compared with those of HAd5 vector in FVB/n mouse model
following intravenous inoculation. The choice of the mouse strain
was based on the fact that we have developed an immunocompetent
FVB/n mouse model for breast cancer to investigate the role of EphA2
receptor tyrosine kinase in tumorigenesis (Noblitt et al., 2005).
Interestingly, the genome copy numbers of BAd3 vector in the heart,
kidney, lung, and spleen were signiﬁcantly (Pb0.05) higher than
those of PAd3 and HAd5 vectors. BAd3 vector also persisted longer inFig. 1. Biodistribution of vector genome at various time points post-inoculation of mice with
viral genome copies per 50 ng of total cellular DNA and were quantitated by real-time PCR. V
⁎Pb0.05 versus BAd-GFP vector genome level at 0.25 day. †Pb0.05 for BAd-GFP versus HAdall tissues examined compared to the other two vectors. The majority
of vector genome was detected in the linear form for all three vectors.
In addition, expression levels of the viral early region gene 4 (E4) and
the late structural gene (hexon) for all three vectors were similar,
indicating leaky vector gene expression and paralleled vector
biodistribution. The results of this study demonstrate that BAd3 and
PAd3 vectors have the potential for in vivo gene delivery applications,
as supplements or alternatives to the currently used HAd vectors.
Results
Vector biodistribution and persistence in mice inoculated with HAd-GFP,
PAd-GFP, or BAd-GFP
The liver and spleen are the main target organs for E1-deleted
Ad vector biodistribution following intravenous delivery (Ni et al., 2005;
Stone et al., 2007) and the number of vector genomes decline drastically
with time (Yang et al., 1994a). To investigate whether nonhuman Ad
vectors based on PAd3 and BAd3 have signiﬁcantly different biodistribu-
tion and persistence from that of HAd5, FVB/n mice were inoculated
intravenously with 1010 vector particles (VP) of HAd-GFP (HAd5 with
deleted E1 and the GFP transgene under the cytomegalovirus (CMV)
promoter) (Bangari andMittal, 2004), PAd-GFP (PAd3 with deleted E1A
and theGFP transgeneunder CMVpromoter) (Bangari andMittal, 2004),HAd-GFP, PAd-GFP, or BAd-GFP. Genome concentrations are expressed as the number of
alues are reported as the mean±standard deviation for three mice at each time point.
-GFP and PAd-GFP at each time point.
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promoter) (Bangari et al., 2005b). At 0.25, 0.5,1, 2, 4, 8, and 16 days post-
inoculation, the mice were sacriﬁced and the liver, spleen, lung, kidney,
and heart were collected. Total cellular DNA extracted from various
tissue samples were analyzed for quantiﬁcation of vector genomes by
real-time PCR speciﬁc to the GFP transgene as it was present in all three
vectors. The sensitivity of this assay was 3 copies of the vector genome
per 50 ng of total cellular DNA. The number of vector genomes and
persistence of BAd-GFP in all tissues were signiﬁcantly (Pb0.05) higher
than those of either PAd-GFP or HAd-GFP except in the liver at 0.25 and
1 days post-inoculationwhere the levelswere somewhat comparable in
all three vector-inoculated mice (Fig. 1). It is interesting to note that
especially in the lung, heart, and kidney, signiﬁcantly high levels of BAd-
GFP genomes persisted even at 16 days post-inoculation (the last time
point examined in the present study). In general, vector genome levels
in PAd-GFP-transduced tissueswere at comparable levels at earlier time
points and signiﬁcantly lower (Pb0.05) or even below the detection
levels at later time points compared to those of HAd-GFP-inoculated
tissues except the heart where the levels were comparable or even
higher at some later timepoints (Fig.1). No vector genomewas detected
in the mock-inoculated mice at any time point (data not shown).
State of vector genomes in mice inoculated with HAd-GFP, PAd-GFP, or
BAd-GFP
The HAd5 vector genome usually persists in episomal form within
the host cell nucleus (Ehrhardt et al., 2003, 2008). However, the vectorFig. 2. (A) Southern blot hybridization strategy to determine the state of the various Ad vec
vector genome maps with the sites for the restriction enzyme that was used to digest the to
genomemaps represent the DNA probes used for Southern blot analyses. The numbers corre
vector genome at various time points in the liver of mice inoculated with HAd-GFP, PAd-GFP,
(n=3) were digested with KpnI, XhoI, or HpaI restriction enzymes, respectively and Souther
the liver of mock-inoculated mouse served as a negative control and puriﬁed vector DNA se
genome of HAd-GFP, PAd-GFP, or BAd-GFP are presented.genome may also get integrated into the chromosomal DNA at a very
low frequency (10−3 to 10−5) (Harui et al., 1999). In order to address
the safety aspect of PAd3 and BAd3 vectors, it was important to
determine the state of their genomes in vivo. To assess the state of
vector DNA in the liver of HAd-GFP, PAd-GFP, or BAd-GFP inoculated
mice, samples of total cellular DNA extracted from the livers collected
at various time points post-inoculation were digested with KpnI (for
HAd-GFP), XhoI (for PAd-GFP), or HpaI (for BAd-GFP) and subjected to
Southern blot analyses. The probes for Southern blot assay were
designed taking into consideration that they differentiate the linear
episomal, circular episomal, and integrated forms of HAd-GFP, PAd-
GFP, or BAd-GFP genome based on the fragment size of restriction
endonuclease (RE)-digested DNA. The sensitivity of the Southern blot
assay, as determined by the amount of vector genome used as a
positive control, was found to be 10 pg of DNA. The expected fragment
sizes for three forms of DNA (linear episomal, circular episomal, and
integrated) were 2.3, 3.4, and N2.3 kb for HAd-GFP, 3, 5, and N3 kb for
PAd-GFP, and 2, 6.8, and N2 kb for BAd-GFP (Fig. 2A). In HAd-GFP, PAd-
GFP or BAd-GFP-inoculated mice, 2.3, 3, or 2 kb speciﬁc bands were
detected up to 2, 1, or 8 days, respectively, suggesting that
predominantly linear forms of the vector genomes were present in
HAd-GFP, PAd-GFP, or BAd-GFP inoculated mice (Fig. 2B). Fragments
of DNA that would correspond to a circular or integrated form of the
vector genomes were not observed even after overexposure of the
Southern blots (data not shown). No signals were detected in samples
from mock-inoculated mice (Fig. 2B). The presence of circular form of
genomes was also investigated by PCR using speciﬁc primer sets fortor genomes in mice liver following systemic inoculation. Schematic diagram showing
tal genomic DNA of HAd-GFP, PAd-GFP, or BAd-GFP. The solid bars parallel to the vector
spond to the nucleotide positions of wild type HAd5, PAd3, or BAd3 genome. (B) State of
or BAd-GFP. 20 μg of the liver DNA from HAd-GFP, PAd-GFP, or BAd-GFP-inoculated mice
n blots were performed with vector-speciﬁc probes. Similarly treated DNA sample from
rved as a positive control. The results of Southern blots showing the linear form of the
Fig. 3. Levels of GFP transgene mRNA expression at various time points post-inoculation of mice inoculated with HAd-GFP, PAd-GFP, or BAd-GFP. Real-time RT-PCR for GFP and
18S rRNA (as an endogenous control for normalization) was performed using 200 ng of total RNA and comparative quantiﬁcation of GFP expression levels was done. Values are
reported relative to mean expression levels observed with HAd-GFP inoculated mice at 0.25 day post-inoculation, considering it as 100 arbitrary units. Values are reported as
the mean±standard deviation for three mice at each time point. ⁎Pb0.05 versus expression level by BAd-GFP at 0.25 day. †Pb0.05 for BAd-GFP versus HAd-GFP and PAd-GFP at
each time point.
Fig. 4. Immunohistochemistry for GFP expression in the liver sections of mice inoculated with HAd-GFP, PAd-GFP, or BAd-GFP. Immunohistochemistry for GFP was performed as
described in the Materials and Methods with the liver sections of mice that were sacriﬁced at 0.25 day (6 h) and 0.5 day (12 h) post-inoculation. The cells expressing GFP are stained
brown. Similar results were obtained with tissue sections from three independent mice.
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Table 1
Serum anti-GFP antibody ELISA titers or Ad-neutralization titers in mice at 16 days post-
inoculation
Vector Anti-GFP ELISA titers Ad-neutralization titers against
homologous virus
1 2 3 1 2 3
HAd-GFP 1:5120 1:5120 1:5120 1:640 1:1280 1:1280
PAd-GFP 1:1280 1:1280 1:5120 1:640 1:1280 1:1280
BAd-GFP 1:1280 1:5120 1:5120 1:1280 1:1280 1:1280
Titers for each individual mouse in the group are listed.
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(data not shown). Sensitivity of the PCR assay for detection of circular
form of HAd5 genome, as determined by using serial dilutions of a
plasmid (pDC-311; Microbix Biosystems, Toronto, ON, Canada) that
contained HAd5 end fragments joint together, was 2.5 pg or 7×105
copies. However, the Southern blot was 25-fold more sensitive as
compared to the PCR assay. The suboptimal sensitivity of PCR could be
due to the presence of two long inverted terminal repeats and the
GC-rich nature of the template resulting in complex secondary
structures. Nevertheless, the results of Southern blot analyses and
PCR indicated that the majority of HAd-GFP, PAd-GFP, or BAd-GFP
genomes remained as linear episomes.Fig. 5. Levels of E4 mRNA expression at various time points post-inoculation of mice inocula
an endogenous control for normalization) was performed using 200 ng of total RNA and co
relative to mean expression levels observed with HAd-GFP inoculated mice at 0.25 day pos
standard deviation for three mice at each time point. ⁎Pb0.05 versus expression level by BAdLevels and duration of transgene expression in various tissues of mice
inoculated with HAd-GFP, PAd-GFP, or BAd-GFP
In vivo efﬁcacy of any gene delivery vector largely depends on
the level and duration of transgene expression. In order to further
substantiate that the persistence of signiﬁcantly high levels of BAd-
GFP genome in multiple organs actually has a positive impact on
transgene expression levels, the total cellular RNA fromvarious tissues
of mice inoculated with HAd-GFP, PAd-GFP, or BAd-GFP were
quantitated for GFP-speciﬁc mRNA transcript levels by real-time
RT-PCR. Levels of transgene expression in BAd-GFP in the lung, heart,
and kidney were signiﬁcantly (Pb0.05) higher than those of either
with PAd-GFP or HAd-GFP (Fig. 3). However, transgene expression in
the liver and spleen of BAd-GFP-inoculated mice were marginally
better only at later time points. In the lung, heart and kidney from
BAd-GFP-inoculated mice, there was signiﬁcantly (Pb0.05) higher
levels of transgene expression that continued at least until 16 days
post-inoculation, consistent with our vector biodistribution data
(Fig. 1). In general, transgene expression levels in various tissues
from PAd-GFP-inoculated mice were comparable to those from
HAd-GFP-inoculated mice at early time points but were signiﬁcantly
lower (Pb0.05) or below detection levels at later time points except in
the heart where the levels were comparablewith both vectors (Fig. 3).ted with HAd-GFP, PAd-GFP, or BAd-GFP. Real-time RT-PCR for E4 mRNA or 18S rRNA (as
mparative quantiﬁcation of E4 mRNA expression levels was done. Values are reported
t-inoculation, considering it as 100 arbitrary units. Values are reported as the mean±
-GFP at 0.25 day. †Pb0.05 for BAd-GFP versus HAd-GFP and PAd-GFP at each time point.
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point (data not shown). In order to detect the GFP protein in tissue
sections, immunohistochemistry was performed. Positive cytoplasmic
staining was observed in hepatocytes of HAd-GFP, PAd-GFP, or
BAd-GFP inoculated mice sacriﬁced at 0.25 and 0.5 day post-
inoculation (Fig. 4), while no staining was detected in PBS-inoculated
mice or controls that did not receive the anti-GFP antibody treatment.
GFP expression by immunohistochemistry was also observed in other
tissues (data not shown).
We were also able to detect substantial levels of anti-GFP ELISA
antibodies (1:1280–1:5120) in the serum samples of HAd-GFP, PAd-
GFP, or BAd-GFP-inoculated mice at 16 day post-inoculation (Table 1).
Similar levels of neutralizing antibodies against HAd5, PAd3, or BAd3
vector were also observed in serum samples collected at 16 days post-
inoculation (Table 1) suggesting that various adenoviral vectors were
equally capable of inducing vector-speciﬁc immunity.
Levels and duration of the early (E4) and late (hexon) gene expression in
various tissues of mice inoculated with HAd-GFP, PAd-GFP, or BAd-GFP
Expression of vector genes at lower levels (“leaky gene expres-
sion”) has been reported in E1-deleted replication defective vectorsFig. 6. Levels of hexon mRNA expression at various time points post-inoculation of mice ino
rRNA (as an endogenous control for normalization) was performed using 200 ng of total R
are reported relative to mean expression levels observed with HAd-GFP inoculated mice at
the mean±standard deviation for three mice at each time point. ⁎Pb0.05 versus expressio
each time point.(Elkon et al., 1997; Kafri et al., 1998; Yang et al., 1994b). Para-
doxically, minimal levels of vector gene expression is better for
vector survival or persistence as it helps to shield the vector-
transduced cells from the host immune surveillance (Russell, 2000;
Yang et al., 1994b). To investigate whether vector gene expression by
nonhuman Ad vectors (BAd-GFP and PAd-GFP) would be comparable
with those of HAd-GFP, the total cellular RNA from various tissues of
mice infected with HAd-GFP, PAd-GFP, or BAd-GFP were quantitated
for E4 or hexon mRNA transcript levels by real-time RT-PCR. We
selected E4 (HAd5 E4 34 kDa open reading frame (orf), PAd3 E4 orf8
and BAd3 E4 orf3) as a representative of an early gene, and hexon as
a representative of a late gene. BAd-GFP E4 expression levels in the
lung, heart and kidney were signiﬁcantly higher (Pb0.05) compared
to levels obtained with PAd-GFP or HAd-GFP (Fig. 5). Whereas, in
the liver and spleen, comparable E4 expression levels were observed
with BAd-GFP or HAd-GFP. PAd-GFP E4 expression was comparable
to that of HAd-GFP E4 in most tissues at least at early time points
(Fig. 5). Similarly, BAd-GFP hexon expression levels in the lung,
heart and kidney were signiﬁcantly higher (Pb0.05) compared to
hexon mRNA levels obtained with PAd-GFP or HAd-GFP (Fig. 6).
However, in the liver and spleen, comparable levels of hexon mRNA
expression were observed with BAd-GFP or HAd-GFP. Expressionculated with HAd-GFP, PAd-GFP, or BAd-GFP. Real-time RT-PCR for hexon mRNA or 18S
NA and comparative quantiﬁcation of hexon mRNA expression levels was done. Values
0.25 day post-inoculation, considering it as 100 arbitrary units. Values are reported as
n level by BAd-GFP at 0.25 day. †Pb0.05 for BAd-GFP versus HAd-GFP and PAd-GFP at
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GFP E4 in most tissues at least at early time points (Fig. 6). No
expression of either E4 or hexon was observed in mock-inoculated
mice (data not shown). Overall, it seemed that levels of the early
and the late gene expression by HAd-GFP, PAd-GFP, or BAd-GFP were
comparable taking into consideration the number of vector genomes
in different tissues at various time points post-inoculation.
Discussion
HAd vectors have demonstrated tremendous potential as a gene
delivery vehicle for vaccine and gene therapy applications. However,
the prevalence of pre-existing vector immunity in the majority of
human population and their predominant hepatotropism may limit
their utility. With the anticipation that nonhuman Ad vectors may
circumvent these limitations, we have developed PAd3 and BAd3
vectors (Bangari and Mittal, 2004; Mittal et al., 1995b). In this study,
we evaluated their biodistribution, persistence, state of vector
genome, and transgene and vector gene expression to further explore
the potential of these nonhuman Ad vectors for gene delivery.
In our study, biodistribution patterns of HAd-GFP in the liver,
spleen, heart, lung, and kidney were similar to the previous ﬁndings
(Alemany and Curiel, 2001; Ni et al., 2005; Stone et al., 2007; Wood
et al., 1999; Zinn et al., 1998). PAd-GFP localized predominantly in the
liver and spleen similar to HAd-GFP. BAd-GFP showed distinct tropism
as indicated by signiﬁcantly (Pb0.05) higher levels of vector
localization to the heart, kidney, and lung compared to PAd3 and
HAd5 vectors, whereas levels of BAd-GFP vector genome in the liver
and spleenwere at levels comparable to those of PAd-GFP or HAd-GFP
at least at earlier time points. The distinct tissue tropismmay partly be
due to utilization of different receptor(s) by BAd3 (Bangari et al.,
2005a). PAd3 and BAd3 vectors internalization is CAR-independent
and there are differences in the transduction efﬁciency of various cell
lines by these vectors compared to HAd5 (Bangari and Mittal, 2005;
Bangari et al., 2005a, 2005b). Recombinant ﬁber knob of HAd5, PAd3,
or BAd3 inhibited cell entry of only homologous virus suggesting that
these three viruses use distinct receptors for internalization (Bangari
et al., 2005a). In addition to CAR, integrins play an important role as
co-receptor in HAd5 entry and hence are likely to be a determinant in
vector biodistribution. Integrin-binding motifs such as Arg–Gly–Asp
(RGD) and Leu–Asp–Val (LDV) are also absent in the penton base of
BAd3 and PAd3 (Reddy et al., 1998) and we have demonstrated earlier
that BAd3 or PAd3 internalization was independent of αvβ3 or αvβ5
integrins (Bangari et al., 2005a).
Despite advancements in the understanding of Ad interactions
with host cell receptors, the exact mechanism of tissue tropism
remains unclear. Various hypotheses have been put forward to explain
the predominant liver tropism exhibited by many Ad vectors. Some of
the non-CAR binding Ad vectors have also been demonstrated to
predominately localize to the liver, suggesting that factors other than
the ﬁber knob–CAR interaction are also involved in mediating
hepatotropism (Alemany and Curiel, 2001; Smith et al., 2002). CAR-
independent uptake of CAR-binding Ad vectors by Kupffer cells or
hepatocytes has been shown (Shayakhmetov et al., 2004). Involve-
ment of certain blood factors (such as coagulation factor IX and
complement components) has been proposed to explain Ad vector
hepatotropism. These factors cross-link Ad vectors with heparan
sulphate proteoglycans (HSPGs) on hepatocytes and thus leading to
preferential hepatotropism. Therefore, modiﬁcation of certain sol-
vent-exposed loops in the ﬁber knob domain of the Ad vector has
resulted in reduced vector uptake in the liver (Shayakhmetov et al.,
2005). Recent studies have demonstrated that HAd5 uptake in the
liver is mediated by binding of coagulation factor X (FX) to hexon
(Kalyuzhniy et al., 2008; Waddington et al., 2008). Moreover, there
were signiﬁcant variations among HAd serotypes to bind to FX, that
correlated with their ability to transduce hepatocytes. Studiesinvestigating interaction of FX and/or other blood factors with PAd3
or BAd3 capsid proteins would further clarify their role in tropism and
biodistribution of these vectors. HSPG-binding motif (KKTK) in the
ﬁber shaft of HAd5 has also been proposed to drive hepatotropism as
deletion of this motif led to signiﬁcant decline in hepatic tissue
transduction (Nicol et al., 2004; Smith et al., 2003a, 2003b). Further-
more, the size and structure of ﬁber may play a role in determining
tissue tropism. Ad vectors with short ﬁbers, like HAd35 and HAd40,
escape hepatic sequestration in contrast to vector with large ﬁbers
(Nakamura et al., 2003; Shayakhmetov et al., 2004). However, a
chimeric HAd5 vector with ovine Ad-derived longshafted ﬁber
demonstrated CAR-independence with no particular preference to
the liver (Nakayama et al., 2006). Nicklin et al. (2005) suggested that
the Ad ﬁber, rather than knob–receptor interaction may contribute to
hepatotropism. BAd3 ﬁber has a very long shaft with few kinks in its
secondary structure and is devoid of (KKTK) motif (Ruigrok et al.,
1994). Though the knob domain has been suggested to be the primary
receptor-seeking moiety of most Mastadenovirus species (Nicklin
et al., 2005), there is a possibility that ﬁber shaft may also play an
important role in BAd3 or PAd3 internalization.
It has been demonstrated that at low doses, Ad vectors were
predominately sequestered by Kupffer cells resulting in suboptimal
transduction of other cell types (Tao et al., 2001). However, the role of
sequestration of Ad vectors by Kupffer cells on vector biodistribution
can be evaluated effectively only at low vector doses. Since there was
no information available on biodistribution of BAd3 and PAd3 vectors
compared to HAd5, we chose a comparatively lower vector dose (1010
VP/mouse) for this study. Our results suggest that sequestration of
BAd3 vector by Kupffer cells did not signiﬁcantly inﬂuenced vector
biodistribution. Subsequent studies with higher vector doses should
further clarify the inﬂuence of reticuloendothelial system on trans-
duction efﬁciencies of these vectors.
BAd-GFP persisted at signiﬁcantly (Pb0.05) higher levels in all
tissues even at 16 days post-inoculation compared to PAd-GFP or
HAd-GFP. It is probably due to better survival of BAd-GFP genome in
various tissues because of slow degradation and/or delayed removal
of cells transduced with the vector genome. PAd-GFP had a similar
biodistribution pattern as HAd-GFP but was present at lower levels in
all tissues and its persistence in various tissues was for a shorter
duration compared to HAd-GFP or BAd-GFP. Whether it is due to
paucity of PAd3 receptors in FVB/n mouse tissues is not clear.
Experiments to investigate the induction of a host innate and adaptive
immune response following intravenous administration of these
vectors are underway.
Because integration of the vector genome may lead to insertional
mutagenesis, we examined the state of the vector genome in the liver
of mice inoculated with HAd-GFP, PAd-GFP, or BAd-GFP. Vector
genome could be present within the cell nucleus as a linear episomal
form, circular episomal form, or integrated into the host genome
(Ehrhardt et al., 2008). It has been reported that the majority of HAd5
genome in transduced cells persists in a episomal form (Ehrhardt
et al., 2003). However, a fraction of the vector genome can also get
integrated into the host chromosomal DNA (Harui et al., 1999). In
addition, the genomes of some HAd serotypes such as HAd12
frequently integrate into the host cell genome mostly by random
integration (Green et al., 1977; Knoblauch et al., 1996). Circularized
vector genomemay also replicate to some extent on its own leading to
its enhanced persistence (Kreppel and Kochanek, 2004). In this study,
only the linear episomal form of HAd-GFP, PAd-GFP, or BAd-GFP
genome was detected suggesting that the majority of nonhuman Ad
genome remained as linear episome similar to the HAd-GFP genome.
BAd-GFP genome as identiﬁed by Southern blot assay persisted at
higher levels up to 8-day-post-inoculation, further corroborating our
results of vector biodistribution and persistence. Additional in vitro
experiments are needed to further explore the state of nonhuman Ad
vector genome.
Table 2
Sequence of primers and Taqman® probes for real-time PCR/RT-PCR for quantiﬁcation
of vector genome and GFP, E4, or hexon mRNA transcripts
Target Primers and probes
GFP Forward primer — 5′-TGGTCCCAATTCTCGTGGAA-3′
Reverse primer — 5′-CCTCTCCGCTGACAGAAAATTT-3′
Probe — 5′-TGGATGGCGATGTGAATGGGCA-3′
HAd5 hexon Forward primer — 5′-CCTACTCTGGCACTGCCTACAA-3′
Reverse primer — 5′-CATCCCATTCGCAAGGATTT-3′
Probe — 5′-CCTGGCTCCCAAGGGTGCCC-3′
PAd3 hexon Forward primer — 5′-GAGACCACCATCGATCCTTTG-3′
Reverse primer — 5′-TGTCTGACCACGAGCTTGGA-3′
Probe — 5′-ATGAGCCCCAACCCCAGCTTG-3′
BAd3 hexon Forward primer —5′-CGGCACGGCCTACAACTC-3′
Reverse primer — 5′-GCCTGCCTAAACTGCGTATTG-3′
Probe — 5′-TTTGCCCCCAACAGTGCCC-3′
HAd5 E4 (34 kDa
orf)
Forward primer — 5′-CCTGCGCTTGTGGTATGATG-3′
Reverse primer — 5′-GCGCTGTATCCAAAGCTCATG-3′
Probe — 5′-CCACGTGGGTTCTGTGGTCCCC-3′
PAd3 E4 (orf 8) Forward primer — 5′-TTCAGGGAGGCGGTGAAC-3′
Reverse primer — 5′-GCGCCTCGAAACATCACACT-3′
Probe — 5′-TGCCCAGCGTGAGTCGCGTG-3′
BAd3 E4 (orf 3) Forward primer — 5′-GGGCGAGCAATCAGCTCTTA-3′
Reverse primer — 5′-CTAATCCACTGCCCATGTACACA-3′
Probe —5′-AGTCCCTGCCCACTTTTGCCTGG-3′
18S rRNA Eukaryotic 18S rRNA Endogenous Control (Catalog number —
4352930E, Applied Biosystems, Foster city, CA)
The probes were labeled with 6-carboxyﬂuorescein (FAM) at the 5′ end and with minor
groove binder (MGB) at the 3′ end.
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the attributes of ﬁrst generation HAd5 vectors. It was expected from
our vector biodistribution and persistence study that GFP transgene
expression by BAd-GFP should be better than that of HAd-GFP or
PAd-GFP. Comparable transgene expression, proportionate to the
levels of vector genome present in the tissue, was observed.
Signiﬁcantly higher (Pb0.05) levels of transgene expression were
detected in the heart, kidney, and lung from BAd-GFP-inoculated mice
and similar levels in the liver and spleen as compared to levels
obtained with HAd-GFP.
Proteins encoded by the E1 region are required for the transactiva-
tion of other vector early and late genes (Russell, 2000), therefore, the
ﬁrst generation E1-deleted Ad vectors are replication defective.
However, leaky expression of the early and late genes of such vectors
has been reported even in the absence of E1 proteins expression
(Elkon et al., 1997; Kafri et al., 1998; Yang et al., 1994b). The leaky
vector gene expression is strong enough to induce vector-speciﬁc
cytotoxic T lymphocyte response leading to the removal of vector-
transduced cells. Unlike HAd-GFP in which the entire E1 region was
deleted, only E1A regions were deleted in PAd-GFP and BAd-GFP
(Bangari and Mittal, 2004; Bangari et al., 2005a). Partial deletion in
the E1 region of PAd-GFP and BAd-GFP was found to be sufﬁcient to
render these vectors replication defective (Bangari and Mittal, 2004;
Reddy et al., 1999a; van Olphen et al., 2002). In the present study,
expression of both vector E4 (early) and hexon (late) genes was
observed by all the three vectors at levels that correspond to the
amount of vector present in various tissues.
Our results in FVB/n mouse model have strongly suggested that
BAd3-based vectors have considerable potential as gene delivery
vector for vaccine and gene therapy. Our recent study involving a
BAd-vector based vaccine in BALB/c mice resulted in signiﬁcantly
higher levels of humoral and cell-mediated immune responses
compared to the HAd5-based vaccine (Singh et al., 2008) suggesting
that the results obtained with FVB/n mouse model are applicable to
another mouse strain. The results presented here have prepared the
foundation for additional studies (with higher vector dose and for
longer duration post-inoculation) for evaluating vector toxicity, and
innate and adaptive immune responses following systemic delivery of
nonhuman Ad vectors.
Materials and methods
Adenoviral vectors
Replication-defective HAd-GFP (Bangari and Mittal, 2004), PAd-
GFP (Bangari and Mittal, 2004) and BAd-GFP (Bangari et al., 2005b)
vectors with deletions in E1 or E1A region and carrying the GFP
gene under the control of the cytomegalovirus (CMV) promoter
were propagated as described previously. HAd-GFP, PAd-GFP, and
BAd-GFP vectors were grown and titrated in 293 (human embryonic
kidney cells expressing HAd E1) (Graham et al., 1977), FPRT HE1
(fetal porcine retina cells expressing HAd E1) (Bangari and Mittal,
2004) and FBRT HE1 (fetal bovine retina cells expressing HAd E1)
(van Olphen et al., 2002), respectively. The virus puriﬁcation was
done by cesium chloride-density gradient centrifugation as pre-
viously described (Bangari and Mittal, 2004). The physical particle
counts of puriﬁed HAd-GFP, PAd-GFP and BAd-GFP vectors were
estimated by spectrophotometry and expressed as vector particles
(VP) per ml following a previously described protocol (Graham
and Prevec, 1995). The VP/plaque forming units (p.f.u) ratio for
HAd-GFP, PAd-GFP and BAd-GFP were 72, 100 and 608 respec-
tively. Since plaque assays for these vectors were carried out in
different cell lines, efﬁciency of plaques formation varied with the
virus and cell type combination. Therefore, VP was selected as the
major criteria for vector quantiﬁcation to maintain consistency with
vector dosage.Animal inoculation
Eight-to-ten-week-old female FVB/n mice were obtained from
Harlan Laboratories (Indianapolis IN). FVB/n mice were selected for
the current study because of the availability of an immunocompetent
tumor model using this strain (Addison et al., 1995; Noblitt et al.,
2005). The use of this strain of mice would allow us to extend our
study for investigation of HAd5, PAd3 and BAd3 vectors in cancer gene
therapy. All animal inoculations were conducted in accordance with
the guidelines and approval from Institutional Biosafety Committee
and Institutional Animal Care and Use Committee. Mice were
inoculated intravenously through tail vein with HAd-GFP, PAd-GFP,
or BAd-GFP at a dose of 1010 VP per mouse in a volume of 100 μl of
PBS++ (Phosphate buffer saline supplemented with 0.01% MgCl2
and 0.01% CaCl2). Mock-inoculated mice served as negative controls.
Mice (3 animals per group) were sacriﬁced at various time points
(0.25, 0.5, 1, 2, 4, 8 and 16 days) post-inoculation. The liver, spleen,
lung, heart, and kidney were collected and stored at −80 °C. These
tissue samples were used for total cellular DNA or RNA extraction for
various assays. Serum samples were also collected for the analysis of
Ad-speciﬁc neutralizing antibody.
Primers and Taqman probes
A set of primer pair and a Taqman® probe speciﬁc to the GFP gene
in HAd-GFP, PAd-GFP, or BAd-GFPwere designed using Primer Express
2.0 software (Applied Biosystems, Foster City, CA). These primers and
probe were used for determining the biodistribution of Ad vectors by
quantiﬁcation of vector genomes by real-time PCR, and analyzing
transgene expression by determining expression levels of GFP mRNA
by real-time RT-PCR.
Similarly, sets of primer pairs and Taqman® probes speciﬁc to the
hexon gene or an E4 gene (HAd5 E4 34 kDa orf, PAd3 E4 orf 8 and BAd3
E4 orf 3) of each vector were designed for quantiﬁcation of their hexon
or E4 mRNA transcripts by real-time RT-PCR. All primer sets and
Taqman® probes were synthesized by Applied Biosystems. The
sequences of various primers and Taqman® probes are in Table 2.
All probes were labeledwith 6-carboxyﬂuorescein (FAM) at the 5′ end
and with minor groove binder (MGB) at the 3′ end.
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Total genomic DNA from 50mg of tissue samples was isolated using
DNeasy kit (Qiagen Inc., Valencia, CA) as per the manufacturer's
guidelines. Initially, standard curves were generated using 10-fold
dilutions (from3 to 3×108 copies) of puriﬁedgenomicDNAofHAd-GFP,
PAd-GFP, or BAd-GFP as a template for real-time PCR using GFP primers
and probe. The copy number of each vector genome was calculated
based on spectrophotometric quantiﬁcation and molecular mass of
vector genomic DNA. Subsequently, these dilutions of each vector were
run as standardswith each set of real-timePCR assay. DNA samples from
mock-inoculated mice tissues served as negative controls. For quanti-
ﬁcation of the vector genome by real-time PCR using the GFP primers
and probe, 50 ng of the total cellular DNA was used in a 25 μl reaction
using Taqman® PCR core reagents (Applied Biosystems). The reaction
mixture contained 10×Taqman® buffer, 250 nM each of forward and
reverse primers, and 100 nM of Taqman® probe along with other
standard kit components. Each reactionwas carriedout induplicate. The
real-time PCR was performed using the Mx3000 Thermocycler
(Stratagene, Cedar Creek, TX). The reaction conditions included
incubation at 50 °C for 2 min, followed by polymerase activation
(95 °C for 10 min), and 45 cycles of denaturation (95 °C for 15 s) and
annealing/extension (60 °C for 1min). The threshold cycle (Ct) value for
individual reactions was determined and data were analyzed with
MxPro software (Stratagene) to obtain the absolute copy number of
viral genome per 50 ng of total cellular DNA.
Quantiﬁcation of GFP, E4, or hexon mRNA transcripts
Total cellular RNA was isolated from 50 mg of each tissue sample
using RNA miniprep kit (Stratagene). RNA samples were treated with
DNase I to remove the residual DNA. 200 ng of total cellular RNA was
processed for real-time RT-PCR using GFP-, E4-, or hexon-speciﬁc
primers and probe and One-step Brilliant QRT-PCR Master Mix Kit
(Stratagene). For normalization of the target gene expression, similar
real-time RT-PCR reactions targeting the endogenous 18S rRNA were
simultaneously carried out in separate tubes. Quantiﬁcation of expres-
sion levels of GFP, E4, or hexon mRNA transcripts in various tissue
sampleswasdonebyΔΔCtmethod (Winer et al.,1999) andexpressed in
relation to the mean expression levels of respective genes observed by
HAd-GFP at 0.25 day post-inoculation (referred to as calibrator). Fold
difference in expression levels in relation to calibrator was calculated as
2−ΔΔCt (where ΔΔCt=[Cttarget gene(unknown)−Ct18S rRNA(unknown)]
− [Cttarget gene(calibrator)−Ct18S rRNA (calibrator)], Ct is the cycle
number at which ﬂuorescence signal crosses the threshold). For
calculation of arbitrary units, the mean expression levels of mRNA
transcripts in HAd-GFP-inoculated mice tissues at 6 h post-inoculation
were considered as 100 arbitrary units. Reaction mixture consisted of
2×QRT-PCRmastermix, 250 nMeach of respective forward and reverse
primers, and 100 nM of Taqman® probe along with other standard kit
components. Each reaction was carried out in duplicate. The real-time
RT-PCR was performed using the Mx3000 Thermocycler. The reaction
conditions included cDNA synthesis step at 50 °C for 30min, followed by
polymerase activation (95 °C for10 min), and 45 cycles of denaturation
(95 °C for 15 s) and annealing/extension (60 °C for 1min). The Ct values
for individual reactions were determined and data were analyzed with
MxPro software to obtain the relative expression levels of GFP, E4, or
hexon mRNA transcripts. All RNA samples were also used for PCR assay
using GFP, E4, or hexon primers and probe to ensure the absence of the
residual DNA.
Southern blot analysis
Total cellular DNA from the livers of mice inoculated with HAd-
GFP, PAd-GFP, BAd-GFP, or PBS was isolated by proteinase-K digestion
and isopropanol precipitation as per previously described method(Sambrook and Russell, 2001). 20 μg of the total cellular DNA was
digested with KpnI (for HAd-GFP inoculated mice), XhoI (for PAd-GFP
inoculated mice), or HpaI (for BAd-GFP inoculated mice) and loaded
on to a 1% agarose gel. DNA from the liver of mock-inoculated mice
and puriﬁed vector DNA were digested similarly and used as negative
and positive controls, respectively. After agarose gel electrophoresis,
the separated DNA fragments were transferred on to a positively
charged nylon membrane (Hybond-N+, GE Healthcare Ltd., Little
Chalfront, UK) by upward capillary transfer method (Sambrook and
Russell, 2001). Following the transfer the DNA fragments were cross-
linked to the membrane by baking at 80 °C for 2 h. DNA hybridization
was performed using HAd5 (nt 34,524–35,537), PAd3 (nt 32,353–
33,582) or BAd3 (nt 32,520–33,615) speciﬁc probes which were
chosen speciﬁcally from the area near the right terminus of the vector
genome to aid in identiﬁcation of the linear, circular, or integrated
form of the vector genome. The probes were prepared by PCR
ampliﬁcation and radiolabeled using [alpha32P]dCTP (MP Biomedi-
cals, Solon, OH) by random priming (DECAprime II kit, Applied
Biosystems). The probes were column puriﬁed (NucAway spin
columns, Applied Biosystems) and used for DNA hybridization at
65 °C overnight in Danhardt's buffer (Sambrook and Russell, 2001).
The membrane was washed twice each with 2×SSC (0.3 M sodium
chloride, 0.03M sodium citrate), 0.1% SDS (Sodium dodecyl sulphate);
1×SSC, 0.1% SDS and 0.1×SSC, 0.1% SDS, wrapped with saran wrap
and exposed to Cyclone Storage Phosphor Screen (Packard Instrument
Company, Meridin, CT). After 2 h of exposure, signals were visualized
by Cyclone Storage Phosphor System (Packard Instrument Company).
Immunohistochemistry
Formalin-ﬁxed and parafﬁn-embedded tissues were deparafﬁ-
nized in xylene and rehydrated using graded dilutions of ethanol
according to standard immunohistochemistry procedures. The slides
were immersed in target retrieval solution (DakoCytomation, Carpin-
teria, CA) at 95 °C for 15 min to retrieve antigens. Endogenous
peroxidase activity was quenched by immersing slides in 3% hydrogen
peroxide solution for 5 min. Endogenous biotin and avidin were
blocked by incubating sections in avidin/biotin blocking reagents
(Vector Laboratories, Burlingame, CA) for 15 min. The sections were
incubated in blocking solution (MOM immunodetection kit, Vector
Laboratories) according to manufacturer's instruction. The sections
were then incubated with a monoclonal anti-GFP antibody (Millipore
Corporation, Billerica, MA) at 1:500 dilution for 30 min at room
temperature followed by a 1:250 dilution of biotinylated anti-mouse
secondary antibody (Vector Laboratories) for 10 min. This step was
followed by incubation with streptavidin–horseradish peroxidase
conjugate (DakoCytomation) for 30 min. Signal ampliﬁcation was
performed by Tyramide Signal Ampliﬁcation Kit (PerkinElmer,
Waltham, MA). The color development was performed by Aminoethyl
Carbazole (Red) Substrate Kit (Zymed Laboratories Inc., San Francisco,
CA). The sections were thoroughly rinsed with tris-buffered saline
(100 mM Tris–HCl, pH 7.5 and 150 mM sodium chloride) in between
each of the above mentioned steps. Counter staining was performed
by dipping slides in hematoxylin solution. The slides were then
thoroughly rinsed with water, mounted with Clearmount solution
(Zymed Laboratories Inc.) and left to drying. The slides were then
cover slipped with Permount (Fisher Scientiﬁc, Pittsburgh, PA).
Detection of Ad-neutralizing antibodies and anti-GFP ELISA antibodies
Serum samples from vector- or PBS-inoculated mice sacriﬁced at
16 days post-inoculationwere collected and tested for the presence of
HAd5-, PAd3-, or BAd3-neutralizing antibodies, as described pre-
viously (Moffatt et al., 2000). Similarly, the serum samples were also
used to detect GFP-speciﬁc antibodies by ELISA as previously
described (Mittal et al., 1995a). Brieﬂy, 96-well ELISA plates (Immulon
53A. Sharma et al. / Virology 386 (2009) 44–542HB, Thermo Scientiﬁc, Asheville, NC) were coated with a puriﬁed
preparation of GFP (1 μg/ml) in carbonate bicarbonate buffer and then
reacted with serial 2-fold dilutions of each of the test serum samples.
Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Bio-
Rad, Hercules, CA) was used as secondary antibody. The optical
density (OD) was measured at 450 nm or 490 nm using an ELISA
reader (Molecular Devices, Sunnyvale, CA). The reciprocal of the
highest serum dilution with an OD reading of at least the mean+2
standard deviation (SD) above the PBS-inoculated mouse serum
sample was taken as the ELISA antibody titer.
Statistical analyses
Student's paired t-tests for multiple comparisons with adjust-
ments in the P-value using Tukey or Bonferroni methods were used
for determining the statistical signiﬁcance. For all tests, Pb0.05 was
considered signiﬁcant.
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